Novartis AG
COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO LAG-3
Last updated:
Abstract:
Combination therapies comprising antibody molecules that specifically bind to LAG-3 are disclosed. The combination therapies can be used to treat, prevent and/or diagnose cancerous or infectious disorders.
Status:
Application
Type:
Utility
Filling date:
30 Sep 2021
Issue date:
19 May 2022